Research programme: p53 - Mdm2/Mdm4 interaction inhibitors - Adamed

Drug Profile

Research programme: p53 - Mdm2/Mdm4 interaction inhibitors - Adamed

Latest Information Update: 08 Jan 2014

Price : $50

At a glance

  • Originator Adamed
  • Class Small molecules
  • Mechanism of Action Proto-oncogene protein c-mdm2 modulators; Tumour suppressor protein p53 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 08 Jan 2014 Research programme: p53 - Mdm2/Mdm4 interaction inhibitors - Adamed is available for licensing as of 08 Jan 2014. http://www.adamed.com.pl/en/r-d/pipeline/
  • 06 Jan 2014 Early research in Cancer in Poland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top